Age-Tailored Infant Formula System with Adaptive HMO Levels

The patent divides the single infant formula into multiple age-specific formulations (0-1 month, 1-2 months, 2-4 months, 4-12 months), each with tailored HMO concentrations. This segmentation allows the nutritional composition to adapt to the infant's changing needs at different developmental stages while maintaining manageable complexity through standardized formulation approaches for each age group.

The patent implements dynamic adjustment of HMO concentrations across different age groups, transitioning from higher concentrations in early infancy to lower concentrations as the infant matures. This dynamic approach mirrors the natural evolution of breast milk composition and aligns nutritional support with the infant's developing digestive and immune systems.

The patent applies local quality by providing different HMO concentrations tailored to specific age groups rather than a uniform concentration. Early infancy formulations (0-2 months) contain lower HMO levels appropriate for developing digestive systems, while later formulations (4-12 months) can incorporate higher concentrations as the infant's tolerance increases, optimizing health benefits while minimizing side effects at each developmental stage.

The patent systematically varies the HMO concentration parameter across different age-specific formulations. By adjusting this critical parameter to match the infant's maturing digestive capacity and nutritional requirements at each age group, the patent maximizes the reliability of health benefits while controlling the risk of digestive adverse effects through progressive parameter optimization.